DE69918145D1 - Verwendung von diltiazem zur behandlung von pathologien der netzhaut - Google Patents

Verwendung von diltiazem zur behandlung von pathologien der netzhaut

Info

Publication number
DE69918145D1
DE69918145D1 DE69918145T DE69918145T DE69918145D1 DE 69918145 D1 DE69918145 D1 DE 69918145D1 DE 69918145 T DE69918145 T DE 69918145T DE 69918145 T DE69918145 T DE 69918145T DE 69918145 D1 DE69918145 D1 DE 69918145D1
Authority
DE
Germany
Prior art keywords
diltiazem
retal
treatment
skin pathologies
pathologies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69918145T
Other languages
English (en)
Other versions
DE69918145T2 (de
Inventor
Serge Picaud
Maria Frasson
Jose Sahel
Henri Dreyfus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Strasbourg filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE69918145D1 publication Critical patent/DE69918145D1/de
Publication of DE69918145T2 publication Critical patent/DE69918145T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
DE69918145T 1998-10-02 1999-10-01 Verwendung von diltiazem zur behandlung von pathologien der netzhaut Expired - Fee Related DE69918145T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9812364A FR2784030B1 (fr) 1998-10-02 1998-10-02 Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR9812364 1998-10-02
PCT/FR1999/002346 WO2000020006A1 (fr) 1998-10-02 1999-10-01 Utilisation du diltiazem pour le traitement de pathologies de la retine

Publications (2)

Publication Number Publication Date
DE69918145D1 true DE69918145D1 (de) 2004-07-22
DE69918145T2 DE69918145T2 (de) 2005-08-11

Family

ID=9531128

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918145T Expired - Fee Related DE69918145T2 (de) 1998-10-02 1999-10-01 Verwendung von diltiazem zur behandlung von pathologien der netzhaut

Country Status (9)

Country Link
US (1) US6716835B1 (de)
EP (1) EP1117408B9 (de)
JP (1) JP2002526411A (de)
AT (1) ATE269085T1 (de)
AU (1) AU5870099A (de)
DE (1) DE69918145T2 (de)
ES (1) ES2219060T3 (de)
FR (1) FR2784030B1 (de)
WO (1) WO2000020006A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
JP2006504715A (ja) * 2002-10-01 2006-02-09 アンマナーティ、パオラ 網膜色素変性症の酵素療法及びそのためのキットの形態をした関連医薬組成物
KR101733773B1 (ko) 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
WO2013010854A2 (en) 2011-07-15 2013-01-24 Solvay Specialty Polymers Italy S.P.A. Fluoropolymer composition for multilayer assemblies
PL3027646T3 (pl) 2013-07-31 2019-03-29 Novartis Ag Nowe wektory selekcyjne i sposoby selekcji eukariotycznych komórek gospodarza
JP6954582B2 (ja) * 2016-12-22 2021-10-27 国立大学法人滋賀医科大学 医薬組成物
FR3081325B1 (fr) 2018-05-23 2020-10-09 Univ Claude Bernard Lyon Diltiazem pour son utilisation dans le traitement des infections microbiennes
WO2020123312A1 (en) * 2018-12-09 2020-06-18 Weinberg Assa Method to prevent and treat macular degeneration by vasodilators
FR3106055B1 (fr) 2020-01-13 2022-01-28 Centre Nat Rech Scient Combinaison de diltiazem et autres agents antiviraux
FR3108033B1 (fr) 2020-03-10 2023-04-21 Univ Claude Bernard Lyon COMPOSES ANTIVIRAUX ET LEURS COMBINAISONS POUR TRAITER L’INFECTION VIRALE PAR LE SARS-CoV-2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006118A1 (en) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Therapeutic use of dihydropyrimidones and benzazepine and benzothiazepine derivatives in retinal or optic nerve dysfunction
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5431907A (en) * 1994-08-03 1995-07-11 Abelson; Mark B. Treatment of vascular disorders of the posterior segment of the eye by topical administration of calcium channel blocking agents
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung

Also Published As

Publication number Publication date
FR2784030B1 (fr) 2002-12-20
ES2219060T3 (es) 2004-11-16
DE69918145T2 (de) 2005-08-11
ATE269085T1 (de) 2004-07-15
EP1117408B1 (de) 2004-06-16
JP2002526411A (ja) 2002-08-20
EP1117408B9 (de) 2004-11-10
EP1117408A1 (de) 2001-07-25
FR2784030A1 (fr) 2000-04-07
WO2000020006A1 (fr) 2000-04-13
US6716835B1 (en) 2004-04-06
AU5870099A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
EP1021179A4 (de) Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE389411T1 (de) Strontium verbindung zur behandlung von sub- dermalem weichteilschmerz
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
EP1079741A4 (de) Implantierbarer gewebeverschluss und system zur behandlung gastroösophagischen rückflusses
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE69918145D1 (de) Verwendung von diltiazem zur behandlung von pathologien der netzhaut
DE69938179D1 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE454451T1 (de) Methode zur behandlung von muskelkrankheiten
DE60213116D1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
ATE275949T1 (de) Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

8339 Ceased/non-payment of the annual fee